Showing results (451-460 of 653) with videos related to
Sort By:
Pageof 66
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 1, 2023
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of FrailtyPriya Vart, Jawad H Butt, Niels Jongs, et al.Diabetic Medicine : a Journal of the British Diabetic Association|September 22, 2022
In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross-sectional 68 Ga-RGD-PET studyJens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, et al.Diabetes, Obesity & Metabolism|December 10, 2016
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trialJohn R Petrie, Nish Chaturvedi, Ian Ford, et al.Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.Frontiers in Endocrinology|December 30, 2021
The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy ControlsJens Christian Laursen, Ida Kirstine B Rasmussen, Emilie H Zobel, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 27, 2022
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysisPhil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, et al.Diabetes Care|January 21, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD StudyPeter Rossing, Ellen Burgess, Rajiv Agarwal, et al.The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialHiddo J L Heerspink, Niels Jongs, Glenn M Chertow, et al.Journal of the American Society of Nephrology : JASN|September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR TrialHiddo J L Heerspink, Di Xie, George Bakris, et al.Plos One|March 17, 2023
Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuriaChristina Gjerlev Poulsen, Daniel G K Rasmussen, Federica Genovese, et al.Pageof 66